Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

By Issue

Search Results

##search.searchResults.foundPlural##

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

13-09-2023

https://doi.org/10.4081/dr.2023.9839

2775

PDF: 990

HTML: 33
Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Paolo Dapavo, Matteo Megna, Marina Talamonti

09-08-2024

https://doi.org/10.4081/dr.2024.9999

1780

PDF: 689

HTML: 99
Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

Karan Rajalingam, Phillip M. Johansen, Nicole J. Levin, Jerry Qi, Oge Marques

11-09-2023

https://doi.org/10.4081/dr.2023.9824

896

PDF: 743

HTML: 35
Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

Vasiliki Tasouli-Drakou, May Nguyen, Hannah Guinn, Omron Hassan, Sneha Butala, Sheshanna Phan

21-11-2022

https://doi.org/10.4081/dr.2022.9492

1699

PDF: 683

HTML: 88
Treatment satisfaction among patients with psoriasis in Saudi Arabia

Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi

15-04-2024

https://doi.org/10.4081/dr.2024.9967

1080

PDF: 575

HTML: 35
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

12-11-2024

https://doi.org/10.4081/dr.2024.10080

1231

PDF: 690

HTML: 31
Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

11-11-2024

https://doi.org/10.4081/dr.2024.10140

1017

PDF: 537

SUPPLEMENTARY MATERIAL: 161

HTML: 18
Atopic dermatitis: a brief review of recent advances in its management

Sultan Daghafak Alenazi

23-05-2023

https://doi.org/10.4081/dr.2023.9678

2425

PDF: 1415

HTML: 119
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

19-05-2023

https://doi.org/10.4081/dr.2023.9692

1073

PDF: 550

HTML: 24
Late reaction to ustekinumab infusion

Marina Resener Morais, Luana Pizarro Meneghello, Carina Flores de Oliveira, André Vicente Esteves Carvalho

e2

09-09-2013

https://doi.org/10.4081/dr.2013.e2

3973

PDF: 672

HTML: 265
Erythrodermic psoriasis improved by tildrakizumab

Giampaolo Trevisan, Lerica Germi, Luigi Naldi

23-11-2022

https://doi.org/10.4081/dr.2022.9448

1161

PDF: 623

HTML: 25
Certolizumab to treat hidradenitis suppurativa

Asem Shadid, Saud Alobaida, Yousef Binamer

27-10-2022

https://doi.org/10.4081/dr.2022.9566

1951

PDF: 735

HTML: 32
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

17-03-2022

https://doi.org/10.4081/dr.2022.9282

1175

PDF: 831

HTML: 44
Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

Fawaz Aljehani, Shumukh Alqahtani, Sara Alharbi, Seham Alsulami

06-12-2024

https://doi.org/10.4081/dr.2024.10171

1730

PDF: 459

HTML: 39
Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

25-06-2020

https://doi.org/10.4081/dr.2020.8642

1379

PDF: 754

HTML: 13
Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

14-03-2022

https://doi.org/10.4081/dr.2022.9091

2638

PDF: 637

HTML: 10
Erythrodermic psoriasis treated with apremilast

John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

19-09-2016

https://doi.org/10.4081/dr.2016.6599

2146

PDF: 974

HTML: 603
Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly

21-11-2022

https://doi.org/10.4081/dr.2022.9265

1553

PDF: 452

HTML: 29
A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain

Judit Riera-Arnau, Daniel Wang, Jordi Mollet, Lucía Bellas, Ricardo Boy, Carlos González-Cruz, Mònica Sabaté, Elena Ballarín, Vicenç García-Patos, Glòria Aparicio

23-06-2026

https://doi.org/10.4081/dr.2026.10247

756

PDF: 237

SUPPLEMENTARY MATERIAL: 13
Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

30-07-2025

https://doi.org/10.4081/dr.2025.10379

444

PDF: 309

HTML: 3
Refractory pityriasis rubra pilaris treated with abrocitinib

Filip Rob

09-01-2025

https://doi.org/10.4081/dr.2025.10105

439

PDF: 290

HTML: 16
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

06-06-2023

https://doi.org/10.4081/dr.2023.9722

809

PDF: 464

HTML: 22
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis: a case-control study

Hao Trong Nguyen, Long Dinh Hoang Vo, Nguyen Nhat Pham

14-07-2022

https://doi.org/10.4081/dr.2022.9516

1690

PDF: 729

HTML: 25
Efficacy of autologous serum therapy in positive and negative autologous serum skin test patients in chronic urticaria in a tertiary care centre

Raghavendra KR, Bangaru H

06-07-2022

https://doi.org/10.4081/dr.2022.9525

2148

PDF: 570

HTML: 66
Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

01-07-2025

https://doi.org/10.4081/dr.2025.10315

566

PDF: 282

HTML: 20

1 - 25 of 46 items 1 2 > >>

Search

Search Results

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

Treatment satisfaction among patients with psoriasis in Saudi Arabia

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

Atopic dermatitis: a brief review of recent advances in its management

Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

Late reaction to ustekinumab infusion

Erythrodermic psoriasis improved by tildrakizumab

Certolizumab to treat hidradenitis suppurativa

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

Erythrodermic psoriasis treated with apremilast

Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain

Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Refractory pityriasis rubra pilaris treated with abrocitinib

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis: a case-control study

Efficacy of autologous serum therapy in positive and negative autologous serum skin test patients in chronic urticaria in a tertiary care centre

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

authors

reviewers

Categories

indexing

dermatopathology